Breast Cancer Stem Cells and Immunogenicity Profile in High-Risk Early Triple-Negative Breast Cancer: A Pilot Study
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26093960 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ariadna Roqué-Lloveras und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Catalan Institute of Oncology Girona, 17007 Girona, Spain. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neoplastic Stem Cells. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: INSTITUTO DE SALUD CARLOS III, Fundació Oncolliga Girona, Fundació Oncolliga Girona and RadikalSwim (OncoSwim).
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is an aggressive subtype requiring further knowledge of biomarkers to improve targeted therapy. A major resistance mechanism involves breast cancer stem cells (BCSCs) evading the immune system. Neoadjuvant or adjuvant chemotherapy may alter BCSCs and the patients’ immune response. We conducted a retrospective study including 29 early-stage TNBC patients resistant to chemotherapy diagnosed at the Catalan Institute of Oncology (Girona, Spain) in 2010–2019. We obtained 44 paired tumor samples (pre- and post-chemotherapy) from the Tumor Biobank, assessing BCSC biomarkers (CD44, CD24, and ALDH1), PD-L1, and percentages of stromal tumor-infiltrating lymphocytes (TILs). Clinicopathological characteristics were also collected. At baseline, 68% of tumors had high CD44 expression, 55% showed low CD24 expression, 9% had high ALDH1 expression, 91% were PD-L1-negative (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Catalan Institute of Oncology Girona, 17007 Girona, Spain.
- Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI), 17190 Salt, Spain.
- New Therapeutic Targets Laboratory (TargetsLab)-Oncology Unit, Medical Science Department, Faculty of Medicine, University of Girona, 17003 Girona, Spain.
- Pathological Anatomy Department, Dr. Josep Trueta University Hospital, 17007 Girona, Spain.
ORCID-Profile: Ariadna Roqué-Lloveras, Emma Polonio-Alcalá, Sira Ausellé-Bosch, Gemma Viñas, Teresa Puig
Förderung
- INSTITUTO DE SALUD CARLOS III
- Fundació Oncolliga Girona
- Fundació Oncolliga Girona and RadikalSwim (OncoSwim)
- pre-doctoral grant to S.A.-B.
Zitieren
APA
Roqué-Lloveras, A., Pérez-Bueno, F., Pozo-Ariza, X., Polonio-Alcalá, E., Ausellé-Bosch, S., Oliveras, G., Viñas, G., & Puig, T. (2025). Breast Cancer Stem Cells and Immunogenicity Profile in High-Risk Early Triple-Negative Breast Cancer: A Pilot Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26093960
Vancouver
Roqué-Lloveras A, Pérez-Bueno F, Pozo-Ariza X, Polonio-Alcalá E, Ausellé-Bosch S, Oliveras G, et al. Breast Cancer Stem Cells and Immunogenicity Profile in High-Risk Early Triple-Negative Breast Cancer: A Pilot Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26093960
BibTeX
@article{RoquLloveras2025,
author = {Roqué-Lloveras, Ariadna and Pérez-Bueno, Ferran and Pozo-Ariza, Xavier and Polonio-Alcalá, Emma and Ausellé-Bosch, Sira and Oliveras, Glòria and Viñas, Gemma and Puig, Teresa},
title = {Breast Cancer Stem Cells and Immunogenicity Profile in High-Risk Early Triple-Negative Breast Cancer: A Pilot Study},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26093960}
}
EUVIMED